Immix Biopharma (Immix Biopharma) Total Assets : $19.93 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Immix Biopharma Total Assets?

Immix Biopharma's Total Assets for the quarter that ended in Dec. 2023 was $19.93 Mil.

During the past 12 months, Immix Biopharma's average Total Assets Growth Rate was 64.20% per year. During the past 3 years, the average Total Assets Growth Rate was 153.10% per year.

During the past 5 years, Immix Biopharma's highest 3-Year average Total Assets Growth Rate was 153.10%. The lowest was 91.60%. And the median was 122.35%.

Total Assets is connected with ROA %. Immix Biopharma's annualized ROA % for the quarter that ended in Dec. 2023 was -96.04%. Total Assets is also linked to Revenue through Asset Turnover. Immix Biopharma's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Immix Biopharma Total Assets Historical Data

The historical data trend for Immix Biopharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immix Biopharma Total Assets Chart

Immix Biopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

0.94

0.54

18.19

14.91

19.93

Immix Biopharma Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial											14.91	13.21	15.57	22.48	19.93

Immix Biopharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Immix Biopharma's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	16.203	+	3.722
	=	19.93

Immix Biopharma's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	16.203	+	3.722
	=	19.93

Immix Biopharma (NAS:IMMX) Total Assets Explanation

Total Assets is connected with ROA %.

Immix Biopharma's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-20.36	/	( (22.475	+	19.925)	/ 2 )
	=	-20.36	/	21.2
	=	-96.04 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Immix Biopharma's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (22.475	+	19.925)	/ 2 )
=	0	/	21.2
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Immix Biopharma Total Assets Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Immix Biopharma (Immix Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064

Website

https://www.immixbio.com

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.

Executives

Jason Hsu	director	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng	director	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Helen C. Adams	director	15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan	director	1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky	director, 10 percent owner	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Ilya M Rachman	director, officer: CEO and Chairman	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris	director, officer: Chief Financial Officer	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Sean Senn	10 percent owner	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin	officer: Scientific Co-Founder	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross	officer: CMO & Head of Clinical Dev.	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064